Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-148

Yes the $$$ numbers relating to some of some of these drugs are large .
Hence the huge numbers talked about IF IMU can kick the right goals

I see people moaning about the spend / cash burn etc , and suspect they
just don't have the vision to put the potential of some of IMU's IP into the context
of the possible value proposition .

I guess the saying "pearls before swine " comes to mind in this context .
But that's how it is .... and hopefully the mind set will change in due course

Sure its a very competitive game and there are no guarantees etc etc
But the theory behind the various IP platforms is brilliant

Breaking into the market for pre existing remedies ,( with Big Pharma "cartel like " reach into the treatment mechanisms ...processes and institutions) isn't easy .

It was never going to be .

Meanwhile if something does work well .... it will get noticed .

IF something is actually deemed as "Game Changing " ...... well these threads will take on another persona

LOL